Barclays analyst Andrew Mok raised the firm’s price target on Humana (HUM) to $255 from $253 and keeps an Equal Weight rating on the shares. Against a backdrop of post-election volatility and downward estimate revisions, Barclays expects initial 2025 managed care guidance to “lean conservative and fall short of consensus expectations in many instances,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana price target raised to $288 from $270 at Piper Sandler
- Early notable gainers among liquid option names on January 13th
- CMS expects 4.33% increase in Medicare Advantage rates in 2026
- CMS likely to release 2026 MA rates Friday, says Wolfe Research
- Humana price target raised to $290 from $260 at Truist